<DOC>
	<DOC>NCT01462344</DOC>
	<brief_summary>The purpose of this study is to assess whether the risk of serious asthma-related events (asthma-related hospitalizations, endotracheal intubations, and deaths) in children 4-11 years old taking inhaled fluticasone propionate/salmeterol combination is the same as those taking inhaled fluticasone propionate alone.</brief_summary>
	<brief_title>6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old</brief_title>
	<detailed_description>Progress of Enrollment, Updated Annually: This study has been completed and the final clinical study report was submitted to the FDA in May of 2016. This is the final update, as this study is complete.</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>1. Consent to participate in the study 2. Age 411 years old 3. Male or eligible female Female subjects should not be enrolled if they are pregnant, lactating or plan to become pregnant during the time of study participation 4. Asthma diagnosis for at least 6 months 5. Ability to answer questions regarding asthma control and use a metered dose inhaler and DISKUS 6. A history of clinical varicella infection or recipient of a varicella vaccine in countries where the product label includes a warning regarding more serious chickenpox infections in patients using corticosteroids. 7. History of at least once occurrence of asthma exacerbation within the prior 12 months 8. Currently being treated for asthma and no change in asthma therapy for the last 4 weeks (Eligible subjects include: subjects with use of shortacting betaagonist, leukotriene receptor antagonist, theophylline, or cromolyn whose asthma is not wellcontrolled; subjects on lowdose ICS monotherapy whose asthma is not wellcontrolled; subjects on lowdose ICS and one or more adjunctive therapy whose asthma is either controlled or not wellcontrolled asthma; subjects on mediumdose ICS monotherapy whose asthma is either controlled or not wellcontrolled; and subjects on mediumdose ICS and one or more adjunctive therapy whose asthma is wellcontrolled) 1. History of lifethreatening asthma 2. Unstable asthma 3. Current use of highdose ICS or ICS/LABA therapy to treat asthma symptoms 4. Concurrent respiratory disease: Current evidence of pneumonia, pneumothorax, atelectasis, pulmonary fibrotic disease, allergic bronchopulmonary aspergillosis, cystic fibrosis, bronchopulmonary dysplasia, or other severe respiratory abnormalities other than asthma. 5. Respiratory infection 6. Subjects with only exerciseinduced asthma 7. An asthma exacerbation within the last 4 weeks or more than 4 separate exacerbations in the last 12 months 8. Hospitalization for asthma within 4 weeks or more than 2 hospitalizations within the last 12 months 9. Other current evidence of clinically significant uncontrolled disease/conditions of any body or organ system 10. Neurological or psychiatric disease or history of drug or alcohol abuse of a subject or his/her guardian which in the opinion of the investigator could interfere with the subject's proper completion of the protocol requirements 11. Participation in an interventional study or used any investigational drug for any disease state within the last 30 days 12. Any adverse reaction including immediate or delayed hypersensitivity to any betaagonist, sympathomimetic drug, or any intranasal, inhaled, or systemic corticosteroid therapy, or vehicle contained within these medication 13. Severe hypersensitivity to cow's milk proteins 14. Administration of prescription or over the counter medications that would significantly affect the course of asthma, or interact with sympathomimetic amines such as: antiIgE (omalizumab), anticonvulsants (barbiturates, hydantoins, carbamazepine); polycyclic antidepressants, betaadrenergic blockers; phenothiazines, monoamine oxidase inhibitors, or diuretics 15. Potent cytochrome P450 3A4 (CYP3A4) inhibitors within the last 4 weeks (e.g., ritonavir, ketoconazole, itraconzole) 16. Affiliation with investigator's site, including a immediate family member of the participating investigator, subinvestigator, study coordinator, or employee of the participating investigator. 17. A Child in Care (CiC) is a child who has been placed under the control or protection of an agency, organisation, institution or entity by the courts, the government or a government body, acting in accordance with powers conferred on them by law or regulation.</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>pediatric</keyword>
	<keyword>ADVAIR</keyword>
	<keyword>FLOVENT</keyword>
	<keyword>asthma</keyword>
</DOC>